Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a leading global robotic exoskeleton company, announced today that Thomas Looby has been appointed president and interim chief executive officer, effective immediately. The company also announced the resignation of Nathan Harding from the position of chief executive officer and from the company’s board of directors.
Tom has most recently been president and chief commercialization officer at Ekso Bionics, where he has been responsible for overseeing the operations of the company’s medical business. He joined Ekso Bionics in April 2014 as the company’s chief marketing officer, a role in which he led the development and execution of the company’s global rehabilitation marketing strategy. Prior to joining Ekso Bionics, Tom served as senior vice president and chief marketing officer at Given Imaging, now part of Medtronic, where he was responsible for worldwide market development for PillCam® capsule endoscopy and other novel diagnostics technologies.
“Tom is a health care industry veteran with an excellent track record for growing organizations and successfully building commercial platforms to create value for shareholders,” said Steven Sherman, chairman of Ekso Bionics’ board of directors. “The board of directors has tremendous confidence in Tom and believes that his leadership and commercial expertise will guide Ekso Bionics to enhanced growth and success as we continue to build a market for robotic exoskeletons. On behalf of the entire board of directors, I sincerely thank Nate for his many years of dedication and contributions to Ekso Bionics.”
“After almost 13 years of working to build an exoskeleton industry, co-founding Ekso Bionics and serving as CEO, I feel confident we have assembled a fantastic team; as the company transitions into a commercial entity, I am ready to pursue new ventures,” said Nathan Harding, Ekso Bionics co-founder.
“I appreciate the confidence the founders and board of directors extend to me,” said Tom Looby. “Success in high-tech healthcare markets starts with great technology and then also depends on strategic market development and execution. I am thrilled to build off of the great technology that Nate and Russ have developed. I look forward to working with the Board and entire Ekso Bionics team to sharpen the company’s operational performance, drive commercialization and position Ekso Bionics to achieve its full potential as a new standard of care.” (Original Source)
Shares of EKSO closed yesterday at $0.89. EKSO has a 1-year high of $2.34 and a 1-year low of $0.65. The stock’s 50-day moving average is $0.87 and its 200-day moving average is $1.13.
Ekso Bionics Holdings Inc designs, develops and sells wearable bionic human exoskeletons that have applications in healthcare, industrial, military, and consumer markets.